MYD88 L265P Mutation Detection by PCR, Quantitative
Also known as: MYD88
Use
This test is useful in distinguishing lymphoplasmacytic lymphoma (LPL) from other low-grade B-cell lymphoproliferative disorders which may be in the differential diagnosis. It can also be used in monitoring patients with an LPL diagnosis and a previously identified MYD88 L265P mutation. The MYD88 L265P mutation is present in the majority of cases of lymphoplasmacytic lymphoma and, less commonly, in other B-cell lymphoproliferative disorders.
Special Instructions
If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by an order comment indicating the specimen most appropriate for testing or individual orders for each sample. A Pathologist Block Selection Fee applies if ARUP pathologist chooses the specimen. Multiple specimens without clear instructions will be held until clarification.
Limitations
Mutations in other locations within the MYD88 gene or mutations in other genes will not be detected. The limit of detection for this test is 0.2 percent mutant alleles, corresponding to 0.4 percent heterozygous mutant cells. Results must be interpreted within the context of clinical data and should not be used alone for a diagnosis of malignancy. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US FDA.
New York Approved
Methodology
PCR-based (qPCR)
Biomarkers
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
1 mL
Container
Lavender (EDTA)
Causes for Rejection
Plasma, serum. Specimens collected in anticoagulants other than EDTA. Clotted or grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinitely |
| Refrigerated | 7 days |
| Frozen | Unacceptable |